PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Latest Information Update: 21 Sep 2023
At a glance
- Drugs Busulfan (Primary) ; Decitabine (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Tislelizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 14 Dec 2021 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
- 14 Dec 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 14 Dec 2021 Planned initiation date changed from 1 Nov 2021 to 1 Jan 2022.